| Malignant neoplasm of breast

Kisqali vs Herceptin Hylecta

Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.

Deep comparison between: Kisqali vs Herceptin Hylecta with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsHerceptin Hylecta has a higher rate of injection site reactions vs Kisqali based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Herceptin Hylecta but not Kisqali, including UnitedHealthcare

Category

Kisqali

Herceptin Hylecta

At A Glance

RouteOral

FrequencyOnce daily (21/28-day cycle)

ClassCDK4/6 inhibitor

RouteSC injection

FrequencyEvery 3 weeks

ClassHER2 antagonist

Indications

Malignant neoplasm of breast
Advanced breast cancer

Malignant neoplasm of breast

Dosing

Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.

Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.

Malignant neoplasm of breast 600 mg/10,000 units administered subcutaneously over approximately 2-5 minutes once every three weeks; no loading dose required; adjuvant patients treated for 52 weeks or until disease recurrence, metastatic patients treated until disease progression.

Contraindications

—

Drug Interactions

1170View drug interactions

1202View drug interactions

Adverse Reactions

Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain

Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia

Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS

Most common (>=10%) Alopecia, nausea, administration-related reactions, neutropenia, diarrhea, asthenia, fatigue, vomiting, myalgia, decreased appetite, stomatitis, arthralgia, headache, rash, constipation, pyrexia, cough, anemia, dyspnea, peripheral sensory neuropathy, leukopenia, mucosal inflammation, hot flush, upper respiratory tract infection

Serious Neutropenia (Grade >=3), febrile neutropenia, leukopenia, left ventricular dysfunction, cardiomyopathy, pulmonary toxicity, hypersensitivity reactions

Postmarketing Administration-related reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome

Pharmacology

Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.

Trastuzumab is a humanized IgG1 kappa monoclonal antibody that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC); hyaluronidase reversibly increases subcutaneous tissue permeability by depolymerizing hyaluronan to enhance systemic absorption of trastuzumab.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Kisqali